Hermetica Superfood Encyclopedia
The Short Answer
Anemone alkaloids from Actinia equina are dominated by homarine, a methylpyridinium alkaloid that inhibits phospholipase A₂ by over 65% and suppresses lipopolysaccharide-induced nitric oxide and reactive oxygen species in macrophage cell cultures. All evidence to date derives exclusively from in vitro studies with no human clinical trials, precluding any validated therapeutic dosing or confirmed clinical benefit in humans.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordanemone alkaloids Actinia equina
Anemone Alkaloids — botanical close-up
Health Benefits
**Phospholipase A₂ Inhibition**: Homarine, the primary alkaloid in A
equina aqueous extracts, inhibited PLA₂ activity by over 65% at concentrations of 0.5–1 mg/mL in vitro, representing a potentially meaningful upstream block of the arachidonic acid inflammatory cascade.
**Nitric Oxide Reduction**
Aqueous extracts of the closely related species Anemonia sulcata, sharing the homarine alkaloid profile, reduced LPS-induced NO production in RAW 264.7 macrophages by 61.85% ± 11.74% at 0.5 mg/mL, suggesting comparable potential for A. equina extracts in inflammatory contexts.
**Reactive Oxygen Species Suppression**
Extracts demonstrated measurable intracellular ROS reduction in macrophage inflammation models, an effect attributable at least in part to homarine's antioxidant-adjacent activity within cellular inflammatory signaling pathways.
**Antimicrobial Properties**: The mucus matrix of A
equina contains hemolytic, cytotoxic, and antibacterial compounds, supporting traditional coastal observations of antimicrobial activity, though the specific molecular targets and active fractions responsible have not been fully characterized for therapeutic application.
**Apoptosis Induction in Macrophages**: At high concentrations (≥1 mg/mL), A
equina extracts triggered caspase-3 and caspase-9-dependent apoptosis in macrophage cell lines, suggesting a concentration-dependent shift from anti-inflammatory modulation to cytotoxic activity that complicates therapeutic window definition.
**Potential Antioxidant Activity**
Homarine and associated compounds in aqueous extracts attenuated oxidative stress markers in LPS-stimulated macrophages, consistent with free-radical scavenging or indirect antioxidant enzyme upregulation, though the precise mechanism has not been elucidated at the molecular level.
Origin & History
Natural habitat
Actinia equina, commonly called the beadlet anemone, is a marine cnidarian indigenous to the intertidal and subtidal zones of the Atlantic Ocean, Mediterranean Sea, and Black Sea, typically anchoring to rocky substrates in shallow coastal waters. Unlike terrestrial botanicals cultivated under controlled agricultural conditions, this species is harvested from wild marine environments, with research specimens collected from rocky shores and tidal pools across European coastlines. No commercial aquaculture or standardized cultivation protocols for medicinal alkaloid production have been established, making wild collection the sole documented sourcing method.
“No formal ethnobotanical or ethnomedical record of Actinia equina alkaloids being deliberately extracted and used as a medicinal preparation by traditional cultures has been identified in the available scientific or anthropological literature. While coastal Mediterranean and Atlantic communities have historically interacted with beadlet anemones as part of marine ecosystems, documented medicinal application of this species' alkaloid fraction is absent from classical herbal pharmacopeias and indigenous medicine compendiums. The primary use context of A. equina in historical records is ecological and culinary rather than therapeutic, with the organism recognized for its striking appearance in tidal pool environments rather than pharmaceutical value. Modern scientific interest in its alkaloids emerged from broader marine bioprospecting efforts in the late twentieth and early twenty-first centuries, driven by growing recognition of marine invertebrates as underexplored sources of bioactive small molecules.”Traditional Medicine
Scientific Research
The entire published evidence base for A. equina alkaloids as a medicinal ingredient consists of in vitro studies using RAW 264.7 murine macrophage cell lines; no animal pharmacokinetic studies, in vivo efficacy models, or human clinical trials have been reported in the available peer-reviewed literature. The most directly relevant published work quantified homarine concentrations in aqueous extracts and measured functional endpoints including NO production, ROS levels, PLA₂ activity, and cell viability across a concentration range of 0.0625–1 mg/mL, yielding quantified effect sizes such as >65% PLA₂ inhibition and 88.81% ± 2.69% reduction in macrophage viability at the highest dose tested. Research on the proteinaceous toxin equinatoxin III has established an LD₅₀ of 83 µg/kg in mice, providing safety-relevant toxicological data but no therapeutic utility data. Overall, the evidence quality is early-stage and preliminary; translation to human therapeutic applications would require dose-ranging studies in animal models, pharmacokinetic characterization, and ultimately randomized controlled trials before any clinical claims could be substantiated.
Preparation & Dosage
Traditional preparation
**Laboratory Aqueous Extract**
0625–1 mg/mL used in published in vitro studies represent research tools, not validated therapeutic doses
Prepared by dissolving lyophilized or fresh tissue in distilled water; experimental concentrations of 0..
**Ethanolic Extract**
Ethanol-based extractions have been employed in laboratory settings to isolate a broader polarity range of bioactive compounds, including alkaloids and lipid-soluble constituents, but no standardization protocols exist.
**Homarine Isolation**
Pure homarine has been studied as an isolated compound in parallel with crude extracts; no commercial standardized homarine supplement form has been documented.
**No Established Human Dose**
5 mg/mL) cannot be directly translated to oral supplemental doses without bioavailability and pharmacokinetic data
Effective and safe human dosing has not been determined; the concentration range showing anti-inflammatory effects in vitro (0.25–0..
**Traditional Preparation**
No documented ethnobotanical or traditional medicinal preparation methods for A. equina alkaloids have been recorded in the available literature; preparation is currently limited to research laboratory extraction techniques.
Nutritional Profile
Actinia equina tissue contains a complex mixture of proteinaceous compounds, glycoproteins, lipids, and small-molecule alkaloids; however, no detailed nutritional composition data (macronutrient or micronutrient breakdown) for A. equina as a food or supplement ingredient has been established in the available literature. The primary pharmacologically characterized small molecule is homarine (N-methyl pyridinium-2-carboxylate), quantified at 0.49 µM per 1 mg/mL of aqueous extract, which is a zwitterionic betaine-class compound also found in various other marine invertebrates and crustaceans. Proteinaceous toxins including equinatoxin III represent a distinct macromolecular fraction with hemolytic and cytotoxic properties rather than nutritional value. Bioavailability of homarine or other alkaloids from crude A. equina extracts via oral administration has not been studied, and the stability of these compounds during digestion, first-pass hepatic metabolism, and systemic distribution remains entirely uncharacterized.
How It Works
Mechanism of Action
Homarine (N-methyl pyridinium-2-carboxylate), the principal alkaloid quantified in A. equina aqueous extracts at approximately 0.49 µM per 1 mg/mL, inhibits phospholipase A₂, the rate-limiting enzyme that cleaves membrane phospholipids to release arachidonic acid and initiate prostaglandin and leukotriene biosynthesis, thereby suppressing upstream inflammatory signaling at concentrations of 0.5–1 mg/mL in cell-based assays. Concomitantly, extracts reduce LPS-induced nitric oxide production in RAW 264.7 macrophages, likely by downregulating inducible nitric oxide synthase (iNOS) expression or activity, and attenuate intracellular ROS accumulation through mechanisms not yet fully resolved at the receptor or gene-expression level. At elevated concentrations, the transition to cytotoxicity appears mediated through caspase-3 and caspase-9 activation, implicating the intrinsic mitochondrial apoptotic pathway as a concentration-dependent endpoint distinct from the anti-inflammatory effects observed at lower doses. Equinatoxin III, a proteinaceous pore-forming toxin also present in A. equina, operates through distinct membrane-disruption mechanisms associated with hemolytic and cardiotoxic effects rather than anti-inflammatory signaling, and is not considered a candidate therapeutic compound.
Clinical Evidence
No human clinical trials investigating A. equina alkaloids or homarine-standardized extracts have been conducted or reported in the peer-reviewed literature as of the available research horizon. All efficacy data originate from single-laboratory in vitro experiments using immortalized murine macrophage lines, which, while mechanistically informative, cannot establish clinical effect sizes, therapeutic doses, or safety profiles in human populations. The in vitro outcomes—including >65% PLA₂ inhibition and approximately 62% NO reduction at sub-milligram concentrations—provide biological plausibility for anti-inflammatory activity but carry low translational confidence without corroborating animal or human data. Confidence in any clinical recommendation is therefore negligible, and the ingredient should be considered investigational rather than evidence-supported for therapeutic use.
Safety & Interactions
Actinia equina extracts exhibit significant dose-dependent cytotoxicity, with 1 mg/mL aqueous extract reducing RAW 264.7 macrophage viability by 88.81% ± 2.69% in vitro, indicating a narrow or absent therapeutic window at concentrations required for maximal anti-inflammatory effect. Equinatoxin III, a pore-forming proteinaceous toxin present in A. equina mucus, carries an established murine LD₅₀ of 83 µg/kg with cardiorespiratory arrest implicated as a toxicity mechanism, representing a serious hazard if crude extracts containing this fraction were administered to humans. Hemolytic activity on rabbit erythrocytes has been documented for A. equina mucus preparations, raising concern for red blood cell integrity that is particularly relevant for any parenteral or concentrated oral formulation. No human drug interaction data, contraindication profiles, or pregnancy and lactation safety assessments have been established; given the cytotoxic and hemolytic potential documented in preclinical models, consumption by humans in any uncharacterized form must be considered unsafe until comprehensive toxicological evaluation is completed.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Actinia equinaBeadlet anemone extractHomarineSea anemone alkaloidsEquinatoxin-bearing extract
Frequently Asked Questions
What is the main active compound in Actinia equina alkaloids?
The primary characterized alkaloid in Actinia equina is homarine (N-methyl pyridinium-2-carboxylate), a methylpyridinium betaine compound quantified at approximately 0.49 µM per 1 mg/mL of aqueous extract. Homarine has demonstrated phospholipase A₂ inhibition exceeding 65% and nitric oxide reduction in macrophage cell cultures, making it the principal candidate for the observed anti-inflammatory effects. Crude extracts also contain proteinaceous toxins such as equinatoxin III, but these are associated with toxicity rather than therapeutic benefit.
Are there any clinical trials on Actinia equina anemone alkaloids in humans?
No human clinical trials investigating Actinia equina alkaloids or any standardized extract derived from this species have been published in the peer-reviewed scientific literature. All existing efficacy data comes from in vitro experiments using RAW 264.7 murine macrophage cell lines, which provides biological plausibility but cannot confirm human safety or therapeutic outcomes. Substantial additional research, including animal pharmacokinetic studies and phase I safety trials, would be required before any human clinical testing could be ethically conducted.
Is it safe to take Actinia equina or beadlet anemone extracts as a supplement?
Actinia equina extracts cannot be considered safe for human supplementation based on current evidence; crude extracts demonstrated 88.81% reduction in macrophage cell viability at 1 mg/mL in vitro, and the mucus fraction exhibited hemolytic activity on erythrocytes. Equinatoxin III, a toxin present in A. equina, has a murine LD₅₀ of 83 µg/kg with cardiorespiratory arrest as a proposed mechanism. No human safety studies, standardized formulations, or established safe dose ranges have been published, and ingestion of uncharacterized preparations must be considered hazardous.
What is homarine and what does it do?
Homarine is a naturally occurring methylpyridinium alkaloid belonging to the betaine class of compounds, found across various marine invertebrates including Actinia equina and related sea anemone species. In laboratory studies, homarine inhibited phospholipase A₂ by over 65% at 0.5–1 mg/mL concentrations, an effect that would theoretically suppress arachidonic acid release and downstream prostaglandin and leukotriene production if reproduced in vivo. However, no pharmacokinetic data on oral bioavailability, tissue distribution, or effective doses in living organisms have been established for homarine derived from A. equina.
How do anemone alkaloids from Actinia equina differ from traditional plant alkaloids used in medicine?
Unlike well-characterized plant alkaloids such as berberine, morphine, or quinine—which have extensive ethnobotanical histories, established pharmacokinetic profiles, and in many cases clinical trial data—A. equina alkaloids like homarine are at the earliest stage of scientific characterization with no traditional medicinal use history documented. Marine-derived alkaloids also differ structurally and in their ecological origin, often co-occurring with proteinaceous toxins and hemolytic compounds that complicate safe extraction and purification for therapeutic use. The research infrastructure, including standardized extraction protocols, bioavailability studies, and regulatory frameworks, that exists for plant alkaloids has not yet been developed for A. equina-derived compounds.
What is the bioavailability of homarine and other alkaloids from Actinia equina extracts?
Homarine and related alkaloids from A. equina are typically delivered via aqueous extraction, which favors water-soluble alkaloid compounds and may enhance gastrointestinal absorption compared to lipophilic plant alkaloids. However, specific oral bioavailability data in humans is limited, with most evidence coming from in vitro studies using direct tissue exposure at concentrations of 0.5–1 mg/mL. The alkaloid profile can vary depending on extraction method and source organism condition, potentially affecting absorption efficiency.
Does Actinia equina anemone alkaloid supplementation interact with anti-inflammatory medications or NSAIDs?
Since homarine inhibits phospholipase A₂ (PLA₂)—a key enzyme upstream of the arachidonic acid inflammatory pathway—concurrent use with NSAIDs or corticosteroids theoretically could create additive effects on inflammation suppression, though this has not been studied in humans. No formal drug interaction studies exist for A. equina alkaloid extracts with prescription medications, making caution advisable for individuals on anticoagulants or platelet-inhibiting drugs. Anyone taking regular medications should consult a healthcare provider before supplementing.
Who would benefit most from Actinia equina anemone alkaloid supplementation based on current research?
Individuals seeking support for inflammatory conditions—particularly those involving PLA₂-mediated pathways such as joint inflammation or inflammatory pain—may theoretically benefit, given the 65%+ PLA₂ inhibition observed in vitro at therapeutic concentrations. However, without human clinical trials, benefits remain theoretical and unproven in any specific population. The extract remains primarily a research-stage ingredient rather than an evidence-backed supplement for targeted conditions.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w anemone-alkaloids-actinia-equina curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
